Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H29NO3 |
| Molecular Weight | 331.4492 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@H](C1)OC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=LCFBCKSQWVQIBY-QSVWIEALSA-N
InChI=1S/C20H29NO3/c1-21-14-8-13-18(15-21)24-19(22)20(23,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17-18,23H,3,6-8,11-15H2,1H3/t18-,20?/m1/s1
| Molecular Formula | C20H29NO3 |
| Molecular Weight | 331.4492 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Propenzolate is a pyridine derivative patented by National Research Development Corp. as an anticholinergic agent. Propenzolate is effective antidotes to the cholinesterase-inhibiting action of various organophosphorus compounds. In clinical trials, Propenzolate has an activity that decreases to some extent the secretion of hydrochloric acid and the volume of gastric juice. Adverse effects, including nausea, vomiting, weakness, and drowsiness, as well as xerostomia and cycloplegia, are observed in a high percentage of patients receiving 0.5 to 1.0 mg. every 12 hours.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13885723
0.5 to 1.0 mg. every 12 hours.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:17:36 GMT 2025
by
admin
on
Wed Apr 02 08:17:36 GMT 2025
|
| Record UNII |
OP853VBF2G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000083301
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
C174806
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
SUB09560MIG
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
3821
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
1334
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
DTXSID701017031
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
4354-45-4
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
OP853VBF2G
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
m438
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2111025
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY | |||
|
118984357
Created by
admin on Wed Apr 02 08:17:36 GMT 2025 , Edited by admin on Wed Apr 02 08:17:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |